NASDAQ:OPGN - OpGen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 694.70 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.38
▲ +0.015 (4.14%)

This chart shows the closing price for OPGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OpGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPGN

Analyst Price Target is $3.00
▲ +694.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OpGen in the last 3 months. The average price target is $3.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 694.70% upside from the last price of $0.38.

This chart shows the closing price for OPGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in OpGen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022HC WainwrightLower Price Target$4.00 ➝ $3.00High
1/12/2022Alliance Global PartnersLower Price Target$4.35 ➝ $3.00High
12/15/2021HC WainwrightReiterated RatingBuy$4.00High
10/22/2021HC WainwrightReiterated RatingBuyMedium
9/30/2021UBS GroupInitiated CoveragePositiveLow
3/15/2021HC WainwrightReiterated RatingBuy$4.00Low
3/2/2021Alliance Global PartnersBoost Price TargetBuy$5.65 ➝ $7.00High
11/13/2020Alliance Global PartnersBoost Price TargetBuy$5.00 ➝ $5.65Low
10/19/2020HC WainwrightReiterated RatingBuyMedium
6/9/2020Alliance Global PartnersReiterated RatingBuy$5.00High
9/9/2019AegisSet Price TargetBuy$20.00Low
5/19/2019HC WainwrightReiterated RatingBuy$1.50High
3/1/2019Alliance Global PartnersInitiated CoverageBuy$2.30Medium
12/5/2018HC WainwrightSet Price TargetBuy$6.00Low
11/14/2018HC WainwrightSet Price TargetBuy$6.00Medium
11/7/2018HC WainwrightSet Price TargetBuy$6.00Low
11/1/2018HC WainwrightSet Price TargetBuy$6.00High
8/3/2018HC WainwrightSet Price TargetBuy$8.00High
5/9/2018HC WainwrightSet Price TargetBuy$9.00High
4/25/2018HC WainwrightSet Price TargetBuy$9.00Low
4/5/2018HC WainwrightSet Price TargetBuy$9.00High
3/16/2018HC WainwrightSet Price TargetBuy$9.00High
2/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$9.00Medium
11/8/2017HC WainwrightReiterated RatingBuy$25.00N/A
10/24/2017HC WainwrightReiterated RatingBuy$25.00N/A
9/11/2017HC WainwrightReiterated RatingBuy$25.00High
8/9/2017HC WainwrightSet Price TargetBuy$25.00High
7/18/2017HC WainwrightSet Price TargetBuy$25.00Low
6/19/2017Dawson JamesReiterated RatingBuyLow
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
OpGen logo
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.38
Low: $0.36
High: $0.39

50 Day Range

MA: $0.60
Low: $0.32
High: $0.88

52 Week Range

Now: $0.38
Low: $0.31
High: $3.72

Volume

146,764 shs

Average Volume

357,475 shs

Market Capitalization

$17.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OpGen?

The following sell-side analysts have issued reports on OpGen in the last twelve months: Alliance Global Partners, HC Wainwright, StockNews.com, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for OPGN.

What is the current price target for OpGen?

0 Wall Street analysts have set twelve-month price targets for OpGen in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 694.7%.
View the latest price targets for OPGN.

What is the current consensus analyst rating for OpGen?

OpGen currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPGN will outperform the market and that investors should add to their positions of OpGen.
View the latest ratings for OPGN.

How do I contact OpGen's investor relations team?

OpGen's physical mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company's listed phone number is (240) 813-1260 and its investor relations email address is [email protected] The official website for OpGen is www.opgen.com. Learn More about contacing OpGen investor relations.